Editorial


Pacific trial: a new ocean or an abnormal wave?

Rolando M. D’Angelillo, Sara Ramella

Abstract

Recently, Antonia et al. (1) have published a phase III randomized trial exploring durvalumab after concurrent chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC).

Download Citation